Equities researchers at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 4.9 %
EVOK stock opened at $5.00 on Wednesday. The stock has a market cap of $42.99 million, a P/E ratio of -2.73 and a beta of 0.38. The stock’s fifty day simple moving average is $5.00 and its two-hundred day simple moving average is $5.85. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $18.60.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The company had revenue of $2.55 million during the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Best Stocks Under $5.00
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 5 Top Rated Dividend Stocks to Consider
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Read Stock Charts for Beginners
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.